• Designation based on clinical evidence indicating INO-3107 may demonstrate substantial improvement over existing therapies
• First Breakthrough Therapy designation for an INOVIO DNA medicine candidate
Read more at prnewswire.comProvided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.